List of Biotech, Pharmaceutical & Life Sciences companies in Illinois - 130

The 2bPrecise platform integrate genomic data withclinical knowledge and genomic research to identify relevant information for clinical care.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

3D ultrasound therapy

Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com.

Adze Biotechnology is a biotechnology company that develops a platform of immunotherapies to treat solid tumors and enhance anti-tumor immunity.

Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

AKAVA Therapeutics is developing first-in-class small molecule therapeutics that inhibit protein aggregation, inhibit enzymes and inhibit cancer for a variety of neurodegenerative diseases.

AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on identifying, acquiring, developing and commercializing therapies for the unmet medical needs of critical care patients and those with severe, often rare, disorders for which few effective treatments are available.

American Medical Technologists (AMT) is a non-profit professional association and certification agency founded in 1939. Based in Rosemont, Illinois, AMT is dedicated to credentialing allied health professionals and supporting their career development. The organization is recognized both nationally and internationally for its commitment to high standards, affordability, and lifelong professional partnerships. AMT offers a range of certification programs for various roles, including Medical Laboratory Scientist, Medical Laboratory Technician, Dental Assistant, Medical Assistant, and Allied Health Instructor. The organization also provides continuing education resources to help professionals maintain their certifications and advance their skills. Additionally, AMT advocates for the allied health profession, offering career guidance and resources for employers and educators to align training programs with industry standards. With a focus on integrity, excellence, and member support, AMT aims to be the preferred choice for allied health certification.

Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new class of supramolecular therapies that instruct cells to initiate regenerative processes and restore function lost from injury, disease, or aging. These therapies contain tens of thousands of biological signals that trigger targeted signaling pathways while forming scaffolds to support tissue growth. Amphix Bio's goal is to use regenerative medicine to increase human healthspans — the length of time that people can live productive, fulfilling lives.

Every day, Aptar creates “a-ha moments” for its customers and their consumers and patients by continually bringing innovations to market that convert non-dispensing packaging into breakthrough product-dispensing systems, including those that give people more effective ways to put on their favorite fragrance, kids the opportunity to pour ketchup without making a mess and patients connected technologies that help them more easily adhere to treatment. Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com. All of Aptar's current job openings are found at jobs.aptar.com. Job applicants should be aware of recruiting scams on the Internet and social media platforms. The scammers frequently use a company’s logo and photos or the names of its executives to give the appearance of legitimacy. The fraud targets job seekers and uses false and fraudulent offers of employment with legitimate employers, like Aptar, to steal from the victims. No applicant for employment with Aptar is ever required to pay any money as part of the job application or hiring process. In addition, Aptar’s recruiting staff sends email communications to job applicants from email addresses with the “@aptar.com” domain name only. To read more about recruiting fraud or to report an incident please see Aptar's Recruiting Fraud Statement. https://aptar.com/careers/recruiting-fraud-statement/

Through our drug development expertise in brain & CNS disorders, we have developed a unique medicinal chemistry platform to discover novel product candidates. The compounds we have discovered work through modulation of NMDA receptors to avoid caustic effects associated with over-activation or full inhibition.

ADM unlocks the power of nature to enrich the quality of life. We're a premier global human and animal nutrition company, delivering solutions today with an eye to the future. We're blazing new trails in health and well-being as our scientists develop groundbreaking products to support healthier living. We're a cutting-edge innovator leading the way to a new future of plant-based consumer and industrial solutions to replace petroleum-based products. We're an unmatched agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. And we're a leader in sustainability, scaling across entire value chains to help decarbonize our industry and safeguard our planet. From the seed of the idea to the outcome of the solution, we give customers an edge in solving the nutritional and sustainability challenges of today and tomorrow. Learn more at www.adm.com.

As a global partner to the biopharmaceutical industry, Asahi Kasei Bioprocess helps biologics manufacturers safely and efficiently produce medicines that patients can trust, by dependably supplying innovative yet exceptionally reliable bioprocess consumables, equipment and scientific support services. Our portfolio is anchored by Planova™ virus removal filters. First released in 1989 as the world's first hollow fiber filter developed specifically for removing viruses from biotherapeutic drug products, Planova™ filters ensure viral safety of biopharmaceutical drug products, thanks to their high quality and consistent performance. Leveraging 30 years of experience, we continue to provide our customers with products, services and expertise to achieve assurance that is beyond expectation. As part of our dedication to solving therapeutic product safety, efficiency and purity challenges, we also manufacture a comprehensive suite of downstream equipment. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, our bioprocessing systems, columns and automation solutions advance GMP manufacturing of critical drug substances around the world. Our portfolio of market-driven equipment and cutting-edge technology touches unit operations across a wide range of therapeutic modalities, including classical small molecule pharmaceuticals, current-generation antibodies, plasma derivatives and next-generation oligonucleotide therapeutics.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company’s pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

ATCOR develops innovative medical devices and digital solutions that help identify and reduce the risk of hypertension, cardiovascular disease (CVD), and other related vascular disorders. Early detection with SphygmoCor® technology allows clinicians to detect target organ damage and manage cardiovascular disease, Alzheimer's, kidney failure, and other vascular diseases. Using SphygmoCor® technology, researchers and clinicians are able to collect and assess clinically relevant digital vascular biomarkers to facilitate routine patient monitoring. These measurements shed insight into subclinical changes in the arterial system that demonstrate the efficacy of clinical trial therapies for chronic vascular diseases. Digital vascular biomarkers provide better prognostic and diagnostic information to target interventions—complementary and additive to—standard brachial blood pressure measurements. For over twenty years, major medical and research institutions have been using SphygmoCor® systems to improve therapeutics and treatment strategies for the world's most devastating chronic diseases. Leading pharmaceutical companies utilize ATCOR devices to collect primary, secondary, and safety endpoint data across all phases of global clinical trials. Playing an integral role in over 4000+ studies to date, our technology has been referenced in over 7000 citations in leading medical journals. ATCOR is a subsidiary of the Australian listed company Cardiex Limited (ASX:CDX) www.cardiex.com

Augmedics pioneers cutting-edge augmented reality technologies to improve surgical outcomes. The company's revolutionary xvision Spine System® allows surgeons to see patients' anatomy as if they have "x-ray vision" and accurately navigate instruments and implants during spine procedures. The first-of-its-kind, FDA-cleared xvision has been used to treat over 4,000 patients and implant more than 20,000 pedicle screws across 21 US states. Augmedics has received numerous honors, including being named a 2021 Index Awards Finalist, a Fast Company World Changing Ideas Awards 2021 Finalist, and one of Time Magazine's Best Inventions of 2020. It was recently featured in The Economist documentary How will businesses use the metaverse? To learn more or schedule an xvision demo, visit augmedics.com.

We work to find new uses for algae as sustainable, natural ingredients for food colorants and flavors; protein powders for plant-based meat; biostimulants to improve yield and quality in vertical farming and growth media to move cell-based food from the laboratory to the table. Based at The Plant in Chicago, BYAS has its own laboratories, production units, photobioreactors and access to a large anaerobic digester.

The measure of our success is in what we achieve together. At BDO, culture is the first order of business. We succeed when we cultivate a conscious and caring corporate culture that puts people at the center of everything we do. In essence, the business of our business is to help people thrive every day. This mindset powers our growth by supporting the development of our people, the success of our clients, and the betterment of our communities. It means taking an expansive view of what's possible, and committing ourselves to achieving exceptional outcomes. At BDO, we are cultivating a culture where our professionals thrive in their work of providing middle market leaders with insight-driven perspectives and assurance, tax and advisory services, helping companies take business as usual to better than usual. BDO is the brand name for the BDO network and for each of the BDO Member Firms. BDO USA, P.C, a Virginia professional corporation, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

Biocatalysts is a biotechnology company producing speciality enzymes at commercial scales for a variety of industries. Biocatalysts has used its wide range of technical, commercial and regulatory capabilities to develop #BiobasedValue for our customers. Established in 1983, Biocatalysts has been a member of the international BRAIN Group since 2018. Next to first-class research and development services for industry customers to create bio-based products and processes, the Group distributes specialty ingredients, like enzymes or bioactive natural products. Own fermentation and production facilities in Continental Europe, UK and the US, together with the associated biotechnological solution competency complete the value chain within the BRAIN Group.

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

BioTechLogic, Inc. is a biopharmaceutical and technology management firm with a unique, proven capability to rapidly and successfully bring products to market through the augmentation and optimization of a corporation's technical resources. We are a team of professionals with expertise in process development, BioAnalytical services, process validation, project management, quality assurance, regulatory submissions and Pre-Approval Inspection (PAI) readiness. Our quality by design (QbD) approach enables us to effectively provide product development support, including: development reports, design of experiments, technology implementation, critical process parameter evaluation, technology transfer and scale-up, and on-site third party contract manufacturing support.

Boston Bioprocess helps biotech companies develop, scale up and optimize fermentation and DSP processes. We aim to remove knowledge and capacity bottlenecks in the transition from lab to commercial manufacturing.

Bravida is redefining what's possible in wound care and infection prevention, with a portfolio of transformative products and technologies that are clinically proven to deliver uncompromising freedom and protection

Bridge to Life was founded with the mission of improving organ transplants through licensing and developing new preservation solutions and technologies to provide the highest quality of service to organ procurement organizations and transplant centers. Bridge to Life is a leading supplier of preservation solutions globally with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, we continue to explore emerging science and preservation technologies.

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease.

Contact: contact@cardiosense.com Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.

CellTrans is pioneering cell therapies for clinical application.

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through design, uncompromising quality standards, and the most technologically advanced manufacturing platforms.

At CF Industries, our mission is to provide clean energy to feed and fuel the world sustainably. The company is headquartered in Northbrook, Illinois, a suburb of Chicago. We operate manufacturing complexes in the United States, Canada, and the United Kingdom, which are among the most cost-advantaged, efficient, and flexible in the world and an unparalleled storage, transportation and distribution network in North America.

Drug Discovery Research Service provider company working out of southwestern Suburbs of Chicago (USA) www.chicagodiscoverysolutions.com. It is the mission of Chicago Discovery Solutions LLC (CDS) to find innovative solutions which will facilitate discovery of innovative drugs and truly applicable green technologies. Our core strength in innovative Chemistry, ability to conceive new pharmacophores, lead generation and optimization of lead molecules for ADME and/or toxicity can help companies involved in drug discovery research. Our scientists have an outstanding track record of achievements in heterocyclic and medicinal chemistry.They have the demonstrated success in starting programs by generating pharmacophores and taking the molecules all the way to clinical trial stages. Chicago Discovery Solutions (CDS) facilitates and accelerates Medicinal Chemistry research by making available special building blocks as privileged structures. Our building blocks are carefully selected and assembled in a constantly updated catalogue. Most of these small 'non-planar' structures provide 3 D exit vectors for substitutions which are very useful for medicinal chemists. We are involved in the development of new and more efficient heterogeeous catalysts for C-C coupling (in-house R&D program).

Since 2005, the Chicago Research Center's dedicated team of qualified, board certified physicians, licensed clinicians, psychometricians and trained support staff have taken part in more than 750 clinical trials over the past 12 years. As an independent research center, CRC specializes in the pharmaceutical and biotechnology industries, focusing their studies in areas including psychiatric, sleep, and general medicine. Located in Portage Park, but serving all of Chicagoland, CRC takes the utmost care to ensure participants of their clinical trials have a safe and rewarding experience. The results of their efforts continue to exceed sponsor expectations for reliability, dependability, human protection, and overall performance. With a combined 25 years of expertise in the industry, Chicago Research Center continues to impact lives through novel developments and provides leadership and continuity to the research industry.

CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).

We're Chicago's first cultivated meat company, working to bring sustainable, cost effective cultivated meat to market. Real Meat, Happier Planet. 🥩 🌍 ✨

Clinical Investigation Specialists, Inc. (CIS), is an independent, premier Clinical Research Management Organization. CIS has conducted Phases I-IV clinical trials for pharmaceutical and biotechnology companies. CIS is committed to providing personalized attention and services by utilizing resources other companies cannot provide. We maintain a proactive pursuit of value added services to meet our clients' changing needs. Our extensive CIS/MD Network consists of the most qualified Board Certified physicians covering all major therapeutic areas. We are proud to break the mold by distinguishing ourselves as a clinical research management organization that is on the cutting edge of medicine. CIS offers not only services you may receive from a CRO & SMO, but also services encompassed by a hands on Research Management Organization. Sounds like a smart choice for companies looking for an efficient means to move their products through the pipeline with more personalized attention. There are many advantages when you choose CIS for your upcoming trials. Our experienced Investigators and Research Coordinators offer innovative ideas every step of the way to help you achieve your desired results.

ClostraBiois dedicated to understanding and treating food allergies and other diseases of the immune system. The company is discovering and developing new therapeutics that modulate the protective ability of the microbiome.

Cloudbyz is focused on building cloud-based products and solutions for life sciences customers, and help them innovate drug development and research to bring therapies faster to market which improve patient health and saves lives. Our innovative digital solutions for Pharmaceuticals, Contract Research Organizations (CRO) and Medical Devices companies helps to digitize research, drug and device development and commercialization. Our suite of products include: 1. Cloudbyz CTMS 2. Cloudbyz CTBM 3. Cloudbyz eTMF 4. Cloudbyz EDC, ePRO & eCOA 5. Patient Recruitment 6. Cloudbyz Safety & PV 7. ClinicalWave.ai (AI based platform for Life sciences organizations) Cloudbyz CTMS, eTMF, EDC, and Safety & Pharmacovigilance are built 100% native on Salesforce cloud platform for sponsors, clinical research organizations (CRO), and Clinical Sites. Cloudbyz Clinical Research Solutions are flexible and scalable to enable to manage and collaboration on clinical trial operations while the intuitive, straightforward design allows rapid deployment with a very intuitive and easy-to-use cloud-based solution. Cloudbyz ITPM offers 360° view and real-time visibility across IT planning, execution, and operations and helps organizations to achieve agility, velocity, innovation, and collaboration across IT and business. Cloudbyz ITPM helps CIO, PMO, and IT leaders to visualize the IT landscape, capability mapping, investment, and operational health in real-time and better align IT initiatives with business.

Cosmos Health Inc. is a global healthcare group that was incorporated in 2009 in Chicago, Illinois. Cosmos Health Inc. is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia, and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Covira is an early-stage biotech company, a spinout from The University of Chicago (Sept 2018). This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira's focus is to develop drugs that work by modulating the biological activity of the gut microbiome's resident bacteria. Covira's lead asset (CS-0003) is a platform technology that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. CS-0003 is transformative to the field and the world is taking notice...in the 4th quarter of last year Business Worldwide Magazine named Covira Among the 2021- Top 20 Most Innovative Companies to Watch.

Covira is an early-stage biotech company, a spinout from The University of Chicago (Sept 2018). This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira's focus is to develop drugs that work by modulating the biological activity of the gut microbiome's resident bacteria. Covira's lead asset (CS-0003) is a platform technology that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. CS-0003 is transformative to the field and the world is taking notice...in the 4th quarter of last year Business Worldwide Magazine named Covira Among the 2021- Top 20 Most Innovative Companies to Watch.

Dimension Inx is the architect of regenerative microenvironments. Our materials give the body a blueprint to heal itself. We take a materials-centric approach to solving patient needs. By creating structures that emulate the body's microenvironment, we elicit an immediate regenerative response. We design for biofunctionality and manufacturability. Our platform is highly adaptable and not limited to any single material. Our collaborative studio approach allows us to co-create a lasting advantage by partnering with leading product and R&D organizations. Contact us to accelerate the development of new regenerative solutions today.

Dystrogen Therapeutics is a clinical stage chimeric cell therapy company focusing on rare diseases. The company is currently testing DEC therapy for Duchenne Muscular Dystrophy.

Elorac, Inc. is a specialty pharmaceutical company devoted to developing, commercializing, and marketing dermatology products. Elorac has over 20 novel prescription products in development. Our products embody proprietary technologies or compounds, all protected by patents or covered by proprietary technology.

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Eton Pharmaceuticals, Inc. is a Deer Park, Illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway. Our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.

Final Mile is the first company in the world to systematically apply behavioral economics and cognitive science to explain and influence human behaviour. Our work spans both commercial and social spaces - Health Care, Consumer Goods, Financial Services, E Commerce, Transportation Safety, Consumer durables and Sanitation. We manage projects across geographies - US, India, France, U.K and Sub-Saharan Africa. Our process involves game-based research, explaining decision making through the lens of Emotions, Heuristics and Context and ultimately translating this understanding into subtle design interventions that influence our non-conscious brain. Project teams are cross functional in nature, comprising Sector/Business specialists, Science specialists and Designers. We are a pioneering a new workplace culture. There are few administrative controls and no complex hierarchies. The culture is one of self discipline, individual accountability, freedom and integrity. Our work has received global recognition. https://www.esomar.org/web/research_papers/In-Depth-Interviews_2789_Red-Alert.php https://www.esomar.org/web/research_papers/In-Depth-Interviews_2725_Belief-Intent-ACTION.php Business Week: http://tinyurl.com/zd9sbw6 The Guardian: http://tinyurl.com/ljr24tx Boston Globe: http://tinyurl.com/448ulh6 Final Mile was recently acquired by Fractal Analytics. This is the amalgamation of behavioral science, artificial intelligence and data science. http://www.zdnet.com/article/fractal-analytics-buys-final-mile-as-ai-data-science-meld-with-behavioral-science/ Visit our website www.thefinalmile.com to learn more about work and expertise.

Grove Biopharma is a preclinical biotechnology startup, pioneering the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets. Our Precision-Linked Proteomimetic therapeutic platform has the potential to address significant unmet medical needs in oncology, neurodegenerative disease, and other rare diseases.

Hargol™ FoodTech, delivering better protein. Healthier and more sustainable complete protein. #ClimateAction #PlanetBasedProtein #CompleteProtein For more information contact: Dror Levy, CEO dror.levy@hargol.com +972-54-762-5508

At HOPPR, we empower developers to build the next generation of AI medical imaging applications, with the goal of making clinical care and workflow optimization more accessible, efficient, and equitable within the healthcare systems they serve.

Innoblative is a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company's SIRA® RFA Electrosurgical Device. The SIRA® device is investigational for use in BCS and is not yet available for sale in the United States. The SIRA® device is cleared for intraoperative coagulation and ablation of soft tissue.

Inomagen Therapeutics is a private, preclinical-stage biotechnology company developing a non-viral gene therapy that targets the underlying mechanisms of atrial fibrillation.

Jaguar Gene Therapy, LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact sizeable patient populations. The company is made up of a proven team of experts with unparalleled CMC (Chemistry, Manufacturing and Controls), regulatory, clinical and commercial acumen who have first-hand experience in bringing novel gene therapy treatments to patients and their families. Committed to patient safety and product purity, Jaguar is rapidly advancing an initial pipeline of three programs targeting: 1) Type 1 galactosemia; 2) a genetic cause of autism spectrum disorder and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and 3) Type 1 diabetes. The company continues to evaluate opportunities to expand its pipeline using the strength of the team and close relationships with numerous academic institutions.

Jointechlabs is a regenerative medicine company that offers point-of-care medical devices enabling safe and cost-effective non-surgical treatments.

LanzaJet is a leading sustainable fuels technology company dedicated to accelerating the energy transition by embracing the circular economy. We are making safe, sustainable fuels from waste and low carbon sources a reality today. We are both an established Sustainable Aviation Fuel (SAF) technology provider, and a sustainable fuels producer. Our patented technology, combined with our extensive know-how and deeply experienced team, makes sustainable fuels a reality today. Through the use of our patented LanzaJetTM Alcohol-to-Jet (AtJ) technology, we are able to create SAF and renewable diesel from waste-based and sustainable ethanol sources. These sources include ethanol created from feedstocks such as low-carbon sugarcane, energy crops, forest residuals, agricultural wastes, and organic waste, just to name a few. There are even existing commercial pathways through our founder, LanzaTech, that can utilize industrial waste gases to create ethanol. With such a widely available starting point, feedstock is readily available and accessible around the world. In this way, we are creating a global, fully circular, carbon recycling economy to enable the decarbonization of the aviation and transportation industries. LanzaJet was formed through the contributions of our investors which include LanzaTech, Suncor Energy Inc., Shell, Mitsui & Co., Ltd., and British Airways and participation from ANA and Breakthrough Energy. The backing from these organizations is significantly accelerating LanzaJet's commercial deployment, and is demonstrating a joint commitment to creating a resilient, lower carbon future. Visit www.lanzajet.com to learn more.

Our way of life is built on carbon, from our fuel sources to the materials in our consumer products, but we need a more sustainable way to source it to protect the future of our planet. LanzaTech Global, Inc. is the carbon recycling company transforming waste carbon into sustainable raw materials for everyday products. Using its biorecycling technology, LanzaTech captures carbon-rich gases generated by energy-intensive industries at the source, preventing them from being emitted into the air. LanzaTech then gives that captured carbon a new life as a sustainable replacement for virgin fossil carbon in everything from household cleaners and clothing fibers to packaging and fuels. By partnering with companies across the global supply chain like ArcelorMittal, Zara, H&M Move and Coty, LanzaTech is paving the way for a circular carbon economy.

Leica Biosystems is proud to be part of Danaher. Danaher's science and technology leadership puts Leica Biosystems' solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. -- Leica Biosystems Privacy Policy can be found at: https://www.leicabiosystems.com/about/privacy-policy/ The collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject, as applicable, to Leica Biosystems' Terms of Use and Privacy Policy. We do not endorse or approve user generated content to promote any other use of our products and will remove any comments or references to such off-label use. We reserve the right to remove a topic or comment at our discretion. By accessing the content, you expressly acknowledge and agree: (1) the content is provided only as a convenience to you and you are accessing the content for your personal educational purposes only; (2) the content may be from a variety of sources over which Leica Biosystems has no control, and should therefore not be interpreted as representing the opinions of, or an endorsement by, Leica Biosystems or its associates; (3) the content is provided to you AS IS, and you release Leica Biosystems of any responsibility or damages you may suffer as a result of the content, including without limitation, any damages resulting from the inaccuracy or unsuitability of the content.

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. Ever since the company started as a family business in the nineteenth century, its instruments have been widely recognized for their optical precision and innovative technology. It is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopes. Leica Microsystems has seven major plants and product development sites around the world. The company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Its headquarters are located in Wetzlar, Germany. Leica Microsystems is proud to be part of Danaher Danaher's science and technology leadership puts solutions from Leica Microsystems at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

People who struggle with hearing loss are at the heart of what we do at Lexie Hearing. With them in mind, we offer a hearing care solution that is affordable and convenient because we do not believe that people should have to spend thousands of dollars on their hearing health. And that's why we're changing the industry. We leverage smart, cutting-edge software technology to bring customers affordable, convenient access to hearing care, as well as a great customer-focused experience with high-quality hearing aids. We believe in healthy hearing for everyone, everywhere.

Madison Scientific, Inc. (MadSci™) is an early-stage medical device company innovating solutions to improve care for individuals with hydrocephalus. The company’s SmartShunt™ Hydrocephalus Management System is designed to be an integrated solution for enabling personalized and informed hydrocephalus management. It features state-of-the-art SmartValve™ technology.

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

Maponos Therapeutics is a cellular therapy company dedicated to development of revolutionary therapeutics for different human diseases, including tissue fibrosis and cancers. We are focused on the cutting-edge technology and discovery of multiple types of cells for innovative and curative treatments. The company was recently cofounded by three faculty members who are affiliated with the University of Chicago School of Medicine and are among leaders in their respective fields. The company licensed the technologies and know-hows from the University of Chicago. The mission of Maponos Therapeutics is to address the unmet medical need by creating innovative treatment with next-generation cell therapeutics.

Maroon Biotech is a biotechnology company that specializes in surfactant chaperones to restore cell structure and viability disrupted by trauma.

Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.

MedGyn Products manufactures and distributes medical devices for the women's healthcare industry including disposables, high quality instruments and equipment to OB/GYN professionals around the world. Our focus on our corporate values has allowed us to continually grow for over two decades as one of the leading suppliers of medical devices for women. Commitment to Innovation We are continually evaluating our product portfolio to drive innovation in healthcare delivery for women. We focus on innovation by leveraging our relationships with professionals to understand procedural techniques and new product development opportunities. As a result, we have received numerous awards and hold several patents on our products. Commitment to Patients and Professionals We are committed to patients and professionals by constantly evaluating procedural techniques to identify products that are less invasive and more effective on women. Our focus is to improve the quality of life for female patients by offering the best medical device technology. Commitment to Our Diverse Team We have a dedicated employee base that is passionate about improving women's health. We strive to provide a collaborative environment to help our employees succeed. We also continually invest in education and training our team to improve our ability to provide superior customer service.

Founded in 2017, Meitheal Pharmaceuticals is a privately owned pharmaceutical company focusing on generic injectable products. Headquartered near Chicago, Illinois, Meitheal has an established management team and an aggressive growth strategy. Through global partnerships, our goal is to bring supply to US healthcare providers that demand a reliable, high quality, yet affordable supply of injectables.

Mezzion is a rare disease company focused on discovering, developing, and delivering new treatments for people living with Fontan circulation. Since its founding in South Korea in 2002, Mezzion has remained dedicated to developing new hope for rare disease patients.

Microbe Detectives, a WaterTrust business, harnesses the power of modern DNA technology to analyze water and wastewater systems in municipal, industrial and agriculture markets. We empower leaders in facilities, technology, and service with knowledge about their water systems that is unprecedented. This translates into improved protection of human health, capital assets, water resources, and the environment at reduced costs. The company is a 2014 graduate of the Water Council's BREW accelerator, winner of the 2015 Wisconsin Innovation Awards and 2017 WEF Gascoigne Award, host of the 2017 Microbiome Water Summit, and was selected to participate in the 2018 WEFTEC/BlueTech Research Innovation Showcase.

Nuclein, LLC was founded in 2017 by experienced biotechnology entrepreneurs Alan Blake and Dr. Richard Crockett. The company's mission is to create a hand-held, disposable, all-in-one, self-test for infectious disease testing, which delivers battery-powered, sample-to-answer results within one hour, without the need to mail in a sample. The company is headquartered in Austin, Texas.

MinXray, Inc. is an independent corporation founded in 1967 that is dedicated to providing compact, portable and mobile x-ray equipment and digital imaging systems where larger units would be impractical or too costly to use. Currently supplying the medical, veterinary, global health, and military imaging markets worldwide, our field transportable digital x-ray systems represent the cutting edge in advanced electronic design. MinXray imaging systems are the ideal solution for mobile imaging providers who perform onsite imaging in nursing homes, prisons, athletic events, remote clinics, or anytime it is more convenient to bring the imaging system to the patient. All units are compatible with conventional and digital imaging modalities.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.

NanoCytomics is a biotechnology company that offers PWS Screening for the early detection of various high incidence cancers, providing a simple and effective process for physicians and patients.

Nephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI).

Northwestern University is a Higher Education institution that offers a wide range of academic programs and research opportunities.

At Nosco, we specialize in creating high-quality printed packaging solutions for the pharmaceutical, home healthcare + OTC, natural health and consumer products markets. With a focus on reliability, quality and responsiveness, we deliver cartons, labels, literature and flexible packaging tailored to each customer's unique needs. Our Brand Promise at Work Through our work together, we provide printed packaging that helps our customers save lives, promote health and encourage happiness. We do this every day with reliability, quality and responsiveness.

A Chicago-based medical device development firm partnering with entrepreneurs, startups and large organizations worldwide to bring their innovations to life.

Opera Bioscience enables Biotech partners to produce high purity proteins and antibodies for therapeutic use, while also minimizing development and manufacturing timelines. By harnessing a bacterial system that can fully secrete proteins out of the cell in a single step, Opera Bioscience can ensure the creation of high-purity proteins from the outset. This approach removes the need for costly and time-consuming downstream processing steps, capitalizing instead on highly efficient continuous fermentation processes. The outcome is a protein manufacturing solution that is both cost-effective and scalable, allowing customers to expedite the launch of their biosimilars and therapeutics while keeping production costs at a minimum.

Founded in research from the University of Chicago, OrisDX has developed a novel non-invasive salivary diagnostic test utilizing biomarker-based molecular genomic techniques to diagnose oral cavity cancers earlier.

Orochem Technologies Inc. has manufactured sample preparation products, chromatography columns, proteomics and oligo research products, and positive pressure processors in the USA since 1996. Orochem offers final products, contract synthesis of resins and oligo, and contract packing services. Orochem provides Simulated Moving Bed (SMB) Chromatography technology for the laboratory scale, pilot scale, and large-scale purification of commercially viable molecules for its customers worldwide. Orochem's products and services for Simulated Moving Bed Chromatography include the synthesis and manufacture of stationary phases "tailored for specific separations", a uniquely engineered SMB system, and the installation and commissioning of the SMB systems at customer sites with well-trained Orochem technical service engineers. Orochem owns several manufacturing facilities around the world. The Naperville, Illinois, USA site has about 84,000 square feet of manufacturing area where most of the Membrane Filter Plates, Silica manufacturing, Silica bonding, Solid Phase Extraction products, and HPLC Columns are manufactured. Orochem India, Mumbai has a 20,000-square-foot facility and manufactures Sample prep products for Discovery and clinical research organizations in Asia. Simulated Moving Bed chromatography systems are designed, built, and assembled completely at our US locations in Naperville Illinois.

Orthogonal is a product development and consulting firm that creates software for medical hardware such as smartphone apps talking to devices that operate directly on the human body to treat sickness and injury. Our solutions take on some of the toughest healthcare problems facing our loved ones, healthcare system, and society. Working at Orthogonal, you will immediately be exposed to projects designed to: •Revolutionize the rapid detection of COVID-19 and other infectious diseases. •Improve the minute-by-minute lives of millions of people suffering from the lifetime affliction of diabetes by managing the delivery of insulin. •Transform the early diagnosis of Alzheimer's disease. •Give patients an at-home means to stimulate specific nerves to treat chronic conditions that drag down their quality of everyday life. •Power the next generation of omics-based cancer-detection systems. Specifically, Orthogonal develops Software as a Medical Device (SaMD), digital therapeutics (DTx), and other types of connected medical devices. We accelerate the product innovation pipeline at medical device, diagnostics, and pharmaceutical manufacturers to modernize patient care and gain competitive advantage. Orthogonal's industry-leading experience with SaMD enables us to rapidly develop, launch, and continuously improve connected, compliant products – and we offer this innovative approach to clients, so they can build their own SaMD product development workflows. Over the last decade, we've worked with partners ranging from startups to Fortune 500 firms to develop and bring their connected devices to market in a highly regulated space.

OWP Pharmaceuticals provides FDA approved epilepsy medications to patients at affordable prices in the United States. We have created a business model that has a significant tie to a "Not for Profit" organization named the ROW Foundation. Through this model both organizations have a vision to drastically improve the lives of epilepsy patients throughout the world including under-resourced patients outside of the United States through increase education, diagnosis and treatment.

Oxalo Therapeutics is a committed to developing first-in-class therapeutics to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia.

Pagari Life Science Corp is a biotechnology company dedicated to the development and commercialization of a new generation of safe anti-herpetic viral drugs and advanced healing drugs. The company is revolutionizing cold sore treatment with the commercial launch of Helocaine®.

The future of mental wellness is being built today. Through its diversified investment fund, Palo Santo is positioned to increase the supply of clinically effective, affordable, and accessible mental health and addiction treatment solutions needed in today's world. Supported by a rapidly growing body of evidence and strong FDA support, psychedelic-assisted treatments represent a paradigm shift in mental health care. Yet the emerging ecosystem of business opportunities is highly fragmented and, with a lack of institutional capital available, Palo Santo is targeting high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams. These businesses are positioned to have a profound impact on treating conditions such as depression, PTSD, anxiety, OCD, drug and alcohol dependence, chronic pain, Alzheimer's, and a range of inflammatory-related illnesses.

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.

Generics

The WHO estimates that by 2020, depression will be the leading cause of disability worldwide. Pax Neuroscience, Inc. is a clinical diagnostics company focused on development and commercialization of blood tests for depression diagnosis and for antidepressant response. These tests are based on novel protein biomarkers derived from hypothesis-driven data sets and early clinical results are promising.

At Pentair, we help the world sustainably move, improve and enjoy water, life’s most essential resource. From our residential and business water solutions, to industrial water management and everything in between, Pentair is focused on smart, sustainable water solutions that help our planet and people thrive. Pentair had revenue in 2023 of approximately $4.1 billion, and trades under the ticker symbol PNR. With approximately 10,500 global employees serving customers in more than 150 countries, we work to help improve lives and the environment around the world. To learn more, visit Pentair.com.

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India. Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement — elements that are key to our success.

Prenosis, decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes

Prompt Praxis Laboratories, LLC, founded in 2011, is a women-owned fully-integrated laboratory powered with the current information technology to facilitate rapid drug testing or development. The emphasis on automation of critical laboratory processes allows PPL to minimize human error within the testing and analysis process. Prompt Praxis Laboratories provides a full range of rapid testing and support services focusing on pharmaceutical products and compounded sterile or nonsterile preparations. Our support activities span three major industries: > Pharmaceutical > Compounding Pharmacy > Medical Devices The scope and breath of the services we offer are extensive, and we anticipate phasing in specialty capabilities based upon the growth of our client base and diversification of development activities. Services in support of other dosage forms may be included in various expansion phases of the laboratory. Prompt Praxis Laboratories, LLC, has developed and validated numerous Ready-to-Analyze® test methods. These methods have been validated to a typical concentration range of 1 to 50 µg/mL with short run times facilitating rapid turnaround. These methods are envisioned to be applicable without further validation to test samples after a quick specificity experiment that demonstrates their utility on the specific samples to be tested. We hope to encourage compliance with the new 503B section of the Food, Drug & Cosmetic Act by cost-effectively providing options to physicians, pharmacies, and outsourcing facilities in an effort to ensure chemically safe and effective compounded preparations.

Protide Pharmaceuticals, Inc. is a fully integrated organization devoted to discovery, development and the advancement of technologies and processes in clinical cell therapy, regenerative medicine, transplantation and cell engineering. With over 35 years of innovative products and services, and hundreds of clinical trials using our technology, we positively impact science through knowledge. Inspired by the scientists, patients, and physicians we support, Protide continues as an entrepreneurial, science driven organization.

Our methods for milling, cutting, steaming and flaking the wholesome, nutritious whole grains in Quaker Products have been perfected over the years. It's what gives us control over the cooking time and texture of each of our products, and guarantees they'll all have that distinct toasted, nutty Quaker flavor.

Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization – from process development and analytical development, to stability services and cGMP API manufacturing. Our facilities are routinely inspected by the FDA and other global regulatory authorities. With our extensive organic chemistry & separations expertise, Regis also manufactures an innovative line of proprietary chromatography products sold throughout the world. Regis is privately owned and operated and has been in business in the Chicagoland area since 1956.

Rhaeos is a VC backed, clinical stage medical device company developing FlowSense, a platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now with FlowSense. FlowSense, is a proprietary wireless, wearable, and noninvasive sensor that can be mounted on skin overlying the shunt to detect the presence and magnitude of CSF. Its miniaturized, thin construction is similar in size to a bandage, and it is composed primarily of soft, silicone rubber with no hard edges. Data is wirelessly transmitted to a custom designed mobile app. Rhaeos received FDA breakthrough designation for FlowSense, is NIH and NSF funded (>$7.5M), published clinical data in Science and Nature family journals, and is on track for initial market entry in 2024. To date, the company has brought in >$19M in dilutive and non-dilutive financing. Follow on products for other chronic conditions are currently in development.

SELAGINE, Inc. develops novel antibody-based biologic eye drops for treatment of immunological or inflammatory ocular surface diseases such as Dry Eye Disease, Sjögren’s syndrome and ocular Graft-versus-Host Disease.

Seurat Therapeutics is focused on developing medication to safely and effectively treat and prevent migraines.

Sibel Health, through engineering excellence, will deliver Better Health Data for All by developing soft, flexible sensors that are powered by advanced analytics, operated by best-in-class software, and integrated with the cloud optimized for artificial intelligence and machine learning.

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.

SkinCure Oncology is the only company offering GentleCure™—the most comprehensive approach to delivering advanced, nonsurgical treatment for basal cell carcinoma, squamous cell carcinoma, and other skin cancers using Image-Guided SRT. The company partners with quality-focused dermatologists and Mohs surgeons to bring cancer center-level radiation therapy to physician offices. From clinical, administrative, and operational backing to robust patient support, SkinCure Oncology ensures that practices are fully equipped to offer treatment with Image-Guided SRT. This advanced technology delivers calibrated doses of X-ray energy via the Sensus SRT-100 Vision™, the first and only skin cancer treatment platform with high-frequency ultrasound imaging. Adaptive radiotherapy protocols destroy malignant cancer cells while preserving healthy tissue surrounding the treated areas for optimal clinical and cosmetic outcomes and the ideal patient experience.

SparX Biopharmaceutical Corp. is a research-based development-stage biopharmaceutical company, dedicated to the mission of “strengthening human immunity using robust antibody therapies” through the discovery and development of innovative immuno-oncology agents. Equipped with big data analytical techniques, such as machine learning algorithms, SparX extracts potential interactions from large volumes of complex multi-dimensional public information. Mechanistic pharmacological analyses coupled with in vitro and in vivo evaluations using the syngeneic, transgenic and humanized mouse models, enables SparX’s focus on developing novel or best-in-class therapeutics demonstrating substantial advantages over existing therapies. Target discovery and validation has historically been the bottleneck in drug development. SparX combines its sophisticated target discovery platform with an integrated multi-component SAILING™ antibody optimization system and a cutting-edge bi-ADC technology to markedly improve the success rate of empowered antibody drug development. In addition to the integrated antibody discovery platform, SparX has built in-house cGMP facilities of significant capacity to produce clinical and commercial drug products, facilitating its evolution into an integrated and independent biopharmaceutical company.

Springfield Clinic is dedicated to preserving the trusted patient-provider relationships we have carefully developed through 84 years of serving you with reliable, primary and specialized health care— close to home. We value the relationships we have built with all of you and are dedicated to preserving the quality and convenience of compassionate health care that you expect and deserve. Our mission is to deliver the highest quality patient care and experience at an exceptional value by recruiting and retaining top medical talent and specialists. We offer the latest innovative treatments and state-of-the-art technologies that would traditionally require treatment in a much larger metropolitan medical center, like St. Louis or Chicago. Our physicians, nurses and employees live, work and take great pride in the 20 counties we serve in central Illinois. We are a community-based organization with more than 650 physicians and advanced practice practitioners delivering care in over 80 medical specialties and sub-specialties. As one of the largest private multispecialty medical clinics in the state, we employ more than 3,000 clinical and administrative employees.

Sunny Biotechnology Co focuses on the development of polyclonal, monoclonal, secondary antibodies, serum-free media and supplements for stem cell research, peptide synthesis service, and related biotech products for life science research and clinical diagnosis.

Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies. Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies.

Sword Bio is a bioanalytical CRO committed to delivering projects with the best-in-class quality, science, service, and speed. We are a team of experts in the bioanalytical CRO field, bringing over 30 years of experience to your project. We specialize in developing, qualifying and validating PK, Biomarkers and immunogenicity assays. At Sword Bio, we have the flexibility to respond to your evolving needs, from assay development to clinical testing in an Non-GLP or GLP environment. We will work with you to maximize your resources and begin your projects immediately, priding ourselves on timely results and open communication. Sword Bio offers a rapid, customized, collaborative and an accessible new way of working with a CRO. Sword’s mission is the same as yours: to quickly and reliably bring essential drugs to those who need them.

Syenex is a synbio technology company that provides genetic medicine developers with access to best-in-class targeted delivery technologies (ex vivo & in vivo). Our goal is to accelerate clinical impact for developers of curative cell and gene therapies

SimBioSys is a pioneering TechBio company leveraging artificial intelligence and biophysical modeling to harness the power of spatial biophysics to redefine precision medicine, transform patient care and defeat cancer. By seeing cancer more completely, SimBioSys aims to empower clinicians and researchers with a more informed understanding of a patient’s tumor to optimally assess all available options and deliver on the promise of truly individualized patient care. To learn more, visit us at https://www.simbiosys.com/.

Syntax Bio is a preclinical-stage biotech company, overcoming longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It's About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

TRACT Therapeutics, Inc. has developed a novel approach for restoring immune balance in patients receiving a solid organ transplant or in patients suffering from an autoimmune disease. This therapeutic approach may potentially reduce the chance of organ rejection following a transplant or transfer a patient suffering from an autoimmune disease into a state of remission. The proprietary technology is based on a platform which can be utilized to treat solid organ transplant patients, as well as a number of autoimmune disorders such as Crohn’s Disease. For organ transplant, it shows great promise in preventing rejection of a donated organ, thereby, reducing the need for a second transplant. Over the next few years, TRACT’s TregCel™ personalized therapy could transform the medical approach in transplant medicine by dramatically reducing or eliminating the lifelong use of toxic anti-rejection drugs.

TRICOR Systems Inc. is an electronic contract manufacturer for medical, aerospace, military and industrial applications. Established in 1976, TRICOR Systems is also a designer and manufacturer of test instrumentation. TRICOR has gained a reputation for innovative design by producing patentable products for others and its own use. TRICOR 's engineers meld electronics, mechanics and optics to produce unique and specialized equipment. The majority of TRICOR 's products have been developed for testing and quality assurance functions in the military, switch, food and light measurement industries. Expertise also includes electronic contract manufacturing for the medical, military, aerospace and industrial markets. TRICOR is an FDA registered, ISO9001:2015 & ISO 13485:2016 AS9100D certified design facility and manufacturer of stock and custom instrumentation products including chocolate temper meters, switch keypad testers, life cycle testers, and inspection systems. Expertise includes electronic contract manufacturing and engineering of electronic systems, circuit cards, SMT, cables and mechanical devices for medical, aerospace, military and industrial applications.

Founded in 2022, UP Oncolytics is engaged in the development of viral vectors to treat refractory and poorly responsive cancers like glioblastoma (GBM) and metastatic melanoma. Despite intensive research efforts, many cancers do not respond to precision therapeutics because of challenges in drug delivery, heterogeneity of the tumor, and an immuno-inhibitory tumor microenvironment. Oncolytic viruses overcome all these challenges. Our initial focus is on GBM, an aggressive brain cancer. Brain cancer is the leading cause of cancer deaths for people under 40 years of age in the United Kingdom, for men under 40 and women under 20 in the United States. In over a century, the overall survival for GBM patients has not significantly changed. The Central Brain Tumor Registry in the United States (CBTRUS) reported that the median survival for adults with GBM is 8 months with 6.8% of patients surviving to 5 years. At UP Oncolytics, we understand new approaches are desperately needed and we are actively working on solutions.

Valent BioSciences LLC is a worldwide leader in the research, development and commercialization of biorational products for the agricultural, public health and forest health markets. Valent BioSciences offers a proprietary and environmentally compatible biorational portfolio including bioinsecticides, biofungicides, bionematicides, mycorrhizal fungi, and plant growth regulators. Biorationals are substances typically derived from biological origins and include biological pesticides, as well as products used for enhanced plant physiology, crop stress management, harvest management and root growth management. The Valent BioSciences team works in close collaboration with its parent company Sumitomo Chemical Co., Ltd. and affiliate companies around the world. Valent BioSciences encourages engagement on this page and reserves the right to remove any perceived inappropriate or offensive posts. Please understand that comments posted by users may or may not represent the opinions of Valent BioSciences.

Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).

Vitalcor, Inc. is a supplier of medical products used primarily in Cardio-Thoracic, Plastic, Nuero, and General Surgery. Vitalcor offers national marketing and selling program directed to surgical gatekeepers and decision makers at hospitals, freestanding sites and integrated healthcare delivery networks. We specialize in high-tech devices for several segments of surgery with a concentration in cardiac surgery.

VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.

At Vyaire, we know that each patient has different goals—and every breath counts to achieve them. We are a company on the move, relentlessly innovating, challenging the status quo and keeping patient needs at the forefront of everything we do to enable, enhance and extend lives. Established from legacy brands with a 70-year history of pioneering breathing technology, Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. We pledge to evolve what’s possible to ensure every breath is taken to its fullest. We pledge to evolve what’s possible to ensure every breath is taken to its fullest. We accomplish this through our values: Patient Purpose, Customer First, Employee Success, and Corporate Integrity. The company’s origin began in the 1950s with the invention of the first mechanical ventilator and has since brought together well-known brands with proven track records of pioneering and advancing respiratory diagnostics and ventilation. Formed in 2016, the unified Vyaire established the world’s largest consortium of experts and industry leaders solely focused on the breathing continuum for customers and patients across the globe. Our passionate, dedicated global workforce consists of experienced breathing specialists who are inspired and empowered to elevate the quality of each inhale and each exhale. Vyaire acknowledges and celebrates the individual backgrounds, perspectives, and voices of our team members to best serve the diverse needs of patients and healthcare providers. Bring your unique talents, commitment, and career aspirations to our global team of dedicated professionals. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families. Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership. We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.

Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.

Zarminali Health is building the nation's leading pediatric multispecialty group, focused on supporting families to shape healthy futures for their children – from birth through adulthood – by completely transforming the way pediatric care is delivered nationwide. We are tackling today's challenges of increased administrative burden on clinicians and a siloed approach to pediatric care through intentional design of care delivery, enhanced by leading technology and collaborative, expert care teams.

ZS is the place where ambitions are welcomed and where passion changes lives. As a management consulting and technology firm focused on transforming healthcare and beyond, we invite you to grow with our global team of bright minds. At ZS, we believe that making an impact demands a different approach; and that's why here your ideas elevate actions, and here you'll have the freedom to define your own path and pursue cutting-edge work. Join us and work side-by-side with like-minded people who rise in care of humanity's greatest challenges to define what's next. To learn more, visit https://www.zs.com/

zuChem is a leading producer of unique sugars for human health and nutrition. zuChem develops proprietary technologies for the manufacture of glycochemicals and carbohydrates for use in the food, specialty and fine chemical markets. The zuChem approach is unique, combining new proprietary technologies with the more traditional synthetic techniques. zuChem researchers have a proven track record in developing and implementing scalable, industrial quality processes.